{"nct_id":"NCT06757634","title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","status":"RECRUITING","status_verified_date":"2025-06","start_date":"2025-06-30","start_date_type":"ESTIMATED","primary_completion_date":"2027-12-31","primary_completion_date_type":"ESTIMATED","completion_date":"2028-12-30","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["CELC"]}